Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing improved versions of FDA-approved chemotherapy drugs designed to reduce toxicity while maintaining or enhancing cancer-killing efficacy. The company uses proprietary technologies to modify the metabolism and distribution of established cancer therapies such as capecitabine and irinotecan, targeting oncology indications including breast, colorectal, lung, and pancreatic cancers, as well as non-oncology conditions like gastroparesis and glomerular diseases. Processa generates revenue through exclusive global licensing agreements with manufacturing and development partners, earning regulatory and sales milestone payments plus tiered royalties on net product sales, while leveraging well-characterized existing therapies to reduce clinical, regulatory, and commercial risk relative to novel drug development.